Catalog Advanced Search
-
Contains 3 Component(s) Includes a Live Web Event on 03/18/2026 at 1:00 PM (EDT)
This webinar addresses advanced Exposure-Response (E-R) analysis strategies to support industrial drug development and evaluate regulatory expectations through real-world case examples. Learners who complete this activity will enhance their knowledge of advanced E-R analysis, interpreting regulatory expectations and integrating case-based best practices.
2026 ACCP STEP & ESP Webinar: Exposure-Response Analysis Across the Drug Development Continuum: Case Examples from Industry & Regulatory Perspective
Live Session: Wednesday, March 18th, 2026, from 1:00 to 2:00 PM ET
On Demand: March 18th, 2026 to March 18th, 2029
Target audience:
Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals who are interested in Exposure-Response (E-R) analysis and practical strategies that can be applied within regulatory, industry, and academic settings.
Objectives
After completing this activity, the learner will be able to:
- Identify common challenges and key considerations for implementing E-R analyses in drug development programs;
- Interpret E-R data to inform dosing strategies and support drug development decision-making;
- Discuss the regulatory expectations on implementation of E-R analyses in regulatory reviews;
Description:
This webinar addresses advanced Exposure-Response (E-R) analysis strategies to support industrial drug development and evaluate regulatory expectations through real-world case examples. Learners who complete this activity will enhance their knowledge of advanced E-R analysis, interpreting regulatory expectations and integrating case-based best practices.
Ahmed Salem, PhD
Senior Research Fellow/Senior Director of Clinical Pharmacology & Pharmacometrics
AbbVie, Inc
Ahmed Salem, PhD, FCP is a Senior Research Fellow/Senior Director of Clinical Pharmacology and Pharmacometrics at Abbvie and an adjunct Professor at University of Minnesota. Dr. Salem is a pharmacist and got his PhD in 2010 from the University of Minnesota with a focus on Pharmacometrics and a minor in Biostatistics. In his industry role, Dr. Salem contributed to 15 different FDA and EMA approvals of new drugs, dosage forms or dosage regimens. He has over 230 publications with an i-10 index of 150 and H index of 45 and holds 10 patents in the US and EU. He has worked on over 200 Phase I, II and III clinical trials. Dr Salem is the recipient of the ACCP Tanabe Investigator Award. He was also the recipient of the AAPS High Impact Article Award in addition to other awards and recognition from the IQ-Clinical Pharmacology Leadership Group (CPLG), UMN and AbbVie. He was also selected as a Fellow of ACCP and as a Senior Research Fellow of the Abbvie Community of Science. Dr. Salem has been an invited speaker and chair at multiple conferences such as ACoP, ASCPT, ACCP, FDA workshops.
Hao Zhu, PhD
Director, Division of Pharmacometrics, Office of Clinical Pharmacology
US Food & Drug Administration
Dr. Hao Zhu is the director of the Division of Pharmacometrics, Office of Clinical Pharmacology, at the U.S. FDA. Dr. Zhu also serves as a selection committee member for Model Informed Drug Development, Complex Innovative Trial Design, and Rare Disease Endpoint Advancement meeting programs. His is a member of Digital Health Technology steering committee at the FDA. He is a co-chair for the AI Policy and Review subcommittee at the CDER FDA. Hao is a board member at the newly formed quantitative medicine center of excellence.
Dr. Zhu received his Ph.D. in pharmaceutical sciences and Master in statistics from the University of Florida. Overall, he has more than 20 years of working experience in academia, industry, and regulatory agency. His division reviews the pharmacometrics related submissions and supports pharmacometrics-related policy development.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 3 Component(s) Includes a Live Web Event on 03/11/2026 at 1:00 PM (EDT)
This webinar addresses gaps in foundational training on core Exposure–Response (E-R) principles relevant to drug development and clinical pharmacology practice. The presentation will explore practical steps to develop credible, fit-for-purpose E-R models aligned with best practices across the drug development continuum. Learners who complete this activity will enhance their knowledge of foundational E-R concepts, strengthening problem solving and critical thinking skills that can be directly applied to clinical pharmacology and regulatory decision-making settings.
2026 ACCP STEP & ESP Webinar: Exposure-Response Analysis Across the Drug Development Continuum: Foundational Principles
Live Session: Wednesday, March 11th, 2026, from 1:00 to 2:00 PM ET
On Demand: March 11th, 2026 to March 11th, 2029
Target audience:
Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals who are interested in the foundational E-R principles and practical strategies that can be applied within regulatory, industry, and academic settings.
Objectives
After completing this activity, the learner will be able to:
- Identify decisions to support, model influence, model risk and model impact;
- Discuss key considerations when creating a qualification plan for Exposure Response (E-R) analyses;
- Identify practical steps to guide the development of credible E-R models.
Description:
This webinar addresses gaps in foundational training on core Exposure–Response (E-R) principles relevant to drug development and clinical pharmacology practice. The presentation will explore practical steps to develop credible, fit-for-purpose E-R models aligned with best practices across the drug development continuum. Learners who complete this activity will enhance their knowledge of foundational E-R concepts, strengthening problem solving and critical thinking skills that can be directly applied to clinical pharmacology and regulatory decision-making settings.
Priya Jayachandran
Quantitative Pharmacologist
Regeneron Pharmaceuticals, Inc.
Priya Jayachandran, PharmD, MSE is a Quantitative Pharmacologist in the Drug Safety and Pharmacometrics Group of Research and Development Sciences at Regeneron Pharmaceuticals, Inc. Prior to her present role, she was a Pharmacometrician in the Global Pharmacometrics Group at Pfizer, Inc. Priya earned a Bachelor of Science in Chemical Engineering from Worcester Polytechnic Institute, a Master of Science in Chemical Engineering from the University of California Berkeley, and a Doctor of Pharmacy from the University of California San Francisco (UCSF). She completed her postdoctoral training at UCSF in the NIH T32 Clinical Pharmacology and Therapeutics Fellowship Program. Priya is an Associate Editor for the ASCPT Journal CPT: Pharmacometrics & Systems Pharmacology and has served in various leadership roles in the ASCPT Networks & Communities. Her professional interests include model-informed drug development, global health, peer education, and scientific communication.
Joga Gobburu
Gyi Endowed Pharmapreneurship Professor
University of Maryland Baltimore (UMB)
Dr. Gobburu is a Gyi Endowed Pharmapreneurship Professor with the School of Pharmacy and the School of Medicine, University of Maryland (UMB), Baltimore, MD, USA. He held various positions at the US FDA between 1999 and 2011. Under his leadership, a Division of Pharmacometrics was formed at the FDA and several policies were established. He is a world-recognized scientific leader in the area of quantitative disease models and their application to decisions. Dr. Gobburu is best known for transforming the field of Pharmacometrics across the world into a decision-supporting science. He also established a Pharmacometrics Fellowship program at the FDA. He received numerous FDA awards such as the Outstanding Achievement Award. He also received the Outstanding Leadership Award from the American Conference on Pharmacometrics (2008), the Tanabe’s Young Investigator Award from the American College of Clinical Pharmacology (ACCP) (2008), the Sheiner-Beal Pharmacometrics Award from the American Society of Clinical Pharmacology and Therapeutics in 2019 and Sheiner Lecture Award from International Society of Pharmacometrics in 2023. He received the UMB Entrepreneur of the Year in 2024. Dr. Gobburu is on the Editorial Boards of several journals and a Fellow of ACCP, AAPS and International Society of Pharmacometrics. He has published over 120 papers and book chapters. He is co-founder of PumasAI Inc., and Vivpro Corporation.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 2 Component(s)
This webinar will examine the role of peer review as a cornerstone of scientific integrity and high-quality biomedical literature. While scientists routinely have their own work peer-reviewed during training and throughout their careers, many have limited exposure to serving as peer reviewers themselves and may not fully understand the process. Join Drs. Joan Korth-Bradley and Mike Fossler as they demystify the peer review process, clarify reviewer expectations and encourage participation in this essential professional responsibility within clinical pharmacology.
2026 ACCP Peer Review: How to Do it to Maintain Quality & Credibility
Live Session: Wednesday, February 11th, 2026, from 1:00 to 2:30 PM ET
On Demand: Wednesday, February 11th, 2026
Target audience:
Clinical pharmacology professionals, including MDs, PharmDs and PhDs or other professionals with little or no experience in performing peer reviews who are interested in learning more about the process.
Description:
This webinar will examine the role of peer review as a cornerstone of scientific integrity and high-quality biomedical literature. While scientists routinely have their own work peer-reviewed during training and throughout their careers, many have limited exposure to serving as peer reviewers themselves and may not fully understand the process. Join Drs. Joan Korth-Bradley and Mike Fossler as they demystify the peer review process, clarify reviewer expectations and encourage participation in this essential professional responsibility within clinical pharmacology.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register
-
Contains 12 Component(s), Includes Credits
The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.
Registration and Pricing
The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.
To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact INFO@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.
Requirements for Credits
All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated in their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits uploaded to the CPE Monitor.
CE Expiration 12/31/2029
-
You must log in to register
- User - $75
- Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
This program provides an overview of ACCP requirements and best practices for planning high-quality continuing education (CE) activities that meet accreditation standards for integrity, independence, and educational effectiveness. Participants will review the Standards for Integrity and Independence, including eligibility criteria for organizations, identification and management of relevant financial relationships, and ACCP’s conflict of interest disclosure processes. The activity also addresses foundational elements of CE design, including selection of appropriate activity types, development of measurable learning objectives aligned with Bloom’s Taxonomy, and integration of active learning strategies. Participants will explore principles of effective assessment design, with an emphasis on distinguishing knowledge-based versus application-based assessments, providing meaningful learner feedback, and avoiding common pitfalls in question writing. Upon completion, learners will have a clearer understanding of how to develop compliant, learner-centered CE activities that align educational content, instructional methods, and assessment strategies to support independent, evidence-based clinical pharmacology education.
Essentials of Planning ACCP Continuing Education Activities - On Demand
Why is this webinar important to your practice?
This program provides an overview of ACCP requirements and best practices for planning high-quality continuing education (CE) activities that meet accreditation standards for integrity, independence, and educational effectiveness. Participants will review the Standards for Integrity and Independence, including eligibility criteria for organizations, identification and management of relevant financial relationships, and ACCP’s conflict of interest disclosure processes.
The activity also addresses foundational elements of CE design, including selection of appropriate activity types, development of measurable learning objectives aligned with Bloom’s Taxonomy, and integration of active learning strategies. Participants will explore principles of effective assessment design, with an emphasis on distinguishing knowledge-based versus application-based assessments, providing meaningful learner feedback, and avoiding common pitfalls in question writing.
Upon completion, learners will have a clearer understanding of how to develop compliant, learner-centered CE activities that align educational content, instructional methods, and assessment strategies to support independent, evidence-based clinical pharmacology education.
Target Audience:
This activity is designed for ACCP committee members, staff and volunteers who are involved in the planning, development or review of ACCP continuing education activities, including those responsible for completing CE planning documentation, developing learning objectives and supporting compliant assessment design.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe ACCP requirements for planning independent continuing education activities, including criteria for eligible and ineligible organizations.
- Apply ACCP guidelines to develop measurable learning objectives that align with the selected CE activity type and accreditation expectations.
- Demonstrate competence in selecting appropriate assessment methods and writing compliant assessment questions that align with stated learning objectives.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 48 Component(s), Includes Credits
The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.
Registration and Pricing
The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.
To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact INFO@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.
Requirements for Credits
All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated in their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits uploaded to the CPE Monitor.
CE Expiration 12/31/2028
-
You must log in to register
- User - $75
- Member - Free!
- More Information
-
You must log in to register
-
Contains 5 Component(s), Includes Credits
This webinar will increase learner knowledge of the effects of diet-and-exercise-induced weight loss on drug-metabolizing enzymes and gastric emptying in patients with obesity. The program will cover drug metabolizing enzymes are affected by diet-and-exercise-induced weight loss in patients with obesity. Learners that complete this webinar will recognize patients with obesity can have lower CYP1A2, CYP2C19, and CYP3A4 activity that counterintuitively implies the need for lower doses of drugs metabolized by these pathways.
2025 ACCP Virtual Journal Club Webinar: Examining the Impact of Diet-and-Exercise-Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity - On Demand
Live Session: Thursday, October 9th, 2025, from 12:00 to 1:00 PM ET
On Demand: October 9th, 2025 to October 9th, 2028
Why is this webinar important to your practice?
This webinar will increase learner knowledge of the effects of diet-and-exercise-induced weight loss on drug-metabolizing enzymes and gastric emptying in patients with obesity. The program will cover drug metabolizing enzymes are affected by diet-and-exercise-induced weight loss in patients with obesity. Learners that complete this webinar will recognize patients with obesity can have lower CYP1A2, CYP2C19, and CYP3A4 activity that counterintuitively implies the need for lower doses of drugs metabolized by these pathways.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in the impact of diet & exercise-induced weight loss on patients with obesity.
Learning Objectives
After completing this activity, the learner will be able to:
- List at least one cytochrome (CYP) enzyme whereby activity increased after weight loss;
- Define the parameter used to assess gastric emptying time;
- Identify at least one single time point metabolic ratio that correlated with exposure (AUC) ratio.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 4 Component(s), Includes Credits
This webinar will explore how pharmacokinetic (PK) bridging is a cornerstone of successful formulation changes, with a specific focus on intravenous (IV) to subcutaneous (SC) transitions. Industry and regulatory experts will examine how the PK landscape has evolved and share practical, forward-looking strategies—including model-informed drug development approaches—to address the complexities of bridging. Real-world case studies will provide insight into what has worked, what hasn’t and why. Whether you're in early development or managing a late-stage formulation shift, this session will equip you with the scientific, regulatory and strategic knowledge needed to implement effective PK bridging and streamline development. Attendees will gain a clear understanding of when PK bridging is essential, how to recognize key decision points and what tools and cross-functional perspectives are shaping the future of route transition in drug development. Learners who complete this activity will have enhanced knowledge in the use of PK bridging strategies in therapeutic drug monitoring.
2025 ACCP STEP & ESP Webinar: Navigating PK Bridging: Essential Strategies for Streamlining Change in Route of Administration in Drug Development
Live Session: Wednesday, June 25th, 2025, from 1:00 to 2:30 PM ET
On Demand: June 25th, 2025 to June 25th, 2028
Target audience:
Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals across the spectrum of academia, industry, regulatory and clinical settings who are interested in the use of PK bridging strategies in therapeutic drug monitoring.
Objectives
After completing this activity, the learner will be able to:
- Recognize the importance and need for PK bridging during therapeutic development;
- Identify key scenarios requiring PK bridging strategies between IV and SC formulations drug drug development;
- Discuss the challenges and opportunities for model-informed PK bridging strategies;
- Describe the multidisciplinary perspectives on PK bridging in practice.
Description:
This webinar will explore how pharmacokinetic (PK) bridging is a cornerstone of successful formulation changes, with a specific focus on intravenous (IV) to subcutaneous (SC) transitions. Industry and regulatory experts will examine how the PK landscape has evolved and share practical, forward-looking strategies—including model-informed drug development approaches—to address the complexities of bridging. Real-world case studies will provide insight into what has worked, what hasn’t and why. Whether you're in early development or managing a late-stage formulation shift, this session will equip you with the scientific, regulatory and strategic knowledge needed to implement effective PK bridging and streamline development. Attendees will gain a clear understanding of when PK bridging is essential, how to recognize key decision points and what tools and cross-functional perspectives are shaping the future of route transition in drug development. Learners who complete this activity will have enhanced knowledge in the use of PK bridging strategies in therapeutic drug monitoring.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 5 Component(s), Includes Credits
This webinar will explore how model-informed drug development (MIDD) techniques are being used to support regulatory approval of new products through the 505(b)(2) pathway. Through detailed case studies, learners will gain practical insight into how the US Food & Drug Administration has accepted model-based justifications for dosing, safety and efficacy, using examples involving fixed-dose combinations, high-potency opioid antagonists and dose optimization in renal or hepatic impairment. Learners that complete this event will understand the significance of model-informed approaches in drug development and regulatory decisions associated with 505(b)(2) submissions.
2025 ACCP Virtual Journal Club Webinar: Driving Efficiency: Leveraging Model-Informed Approaches in 505(b)(2) Regulatory Actions - ON DEMAND
Live Session: Tuesday, June 10th, 2025, from 12:00 to 1:00 PM ET
On Demand: June 10th, 2025 to June 10th, 2028
Why is this webinar important to your practice?
This webinar will explore how model-informed drug development (MIDD) techniques are being used to support regulatory approval of new products through the 505(b)(2) pathway. Through detailed case studies, learners will gain practical insight into how the US Food & Drug Administration has accepted model-based justifications for dosing, safety and efficacy, using examples involving fixed-dose combinations, high-potency opioid antagonists and dose optimization in renal or hepatic impairment. Learners that complete this event will understand the significance of model-informed approaches in drug development and regulatory decisions associated with 505(b)(2) submissions.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in the application of MIDD in regulatory applications.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe applications of model-informed approaches that have been utilized to provide evidence of effectiveness;
- Explain how model-informed approaches have been applied to optimize dosing in patient subgroups;
- Explain how a model-informed approach has been used to inform policy.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 4 Component(s), Includes Credits
Cytokine release syndrome (CRS) is a life-threatening systemic inflammatory syndrome involving elevated levels of circulating cytokines and immune cell hyperactivation that can be triggered by various therapies, pathogens, cancers, autoimmune conditions and monogenic disorders. Many therapeutics such as cancer immunotherapy (CAR-T, CD3 bispecifics, etc.) can lead to CRS. To mitigate the CRS risk, various approaches were investigated in clinical trials, including priming dosing (step-up dosing, split dosing, dose fractionation, etc.) and premedications. Translational modeling approaches such as mechanistic quantitative systems pharmacology models were also developed to optimize the dose in the clinic to minimize the CRS. In addition, CRS could also result in drug-drug interaction (DDI) risks due to the suppression of CYP enzymes and transporters by the proinflammatory cytokines. Physiologically-based pharmacokinetic approaches have been utilized to assess CRS mediated DDI risks. This activity will focus on the current scientific aspects for CRS and its implications in drug development as well as future perspectives. Learners who complete this activity will have enhanced knowledge utilizing case examples and discussions.
ACCP Clinical Practice Webinars: Cytokine Release Syndrome: Implications in Drug Development - On Demand
Live Session: Thursday, May 29th, 2025, from 12:00 to 1:00 PM ET
On Demand: May 29th, 2025 to May 29th, 2025
Why is this webinar important to your practice?
Cytokine release syndrome (CRS) is a life-threatening systemic inflammatory syndrome involving elevated levels of circulating cytokines and immune cell hyperactivation that can be triggered by various therapies, pathogens, cancers, autoimmune conditions and monogenic disorders. Many therapeutics such as cancer immunotherapy (CAR-T, CD3 bispecifics, etc.) can lead to CRS. To mitigate the CRS risk, various approaches were investigated in clinical trials, including priming dosing (step-up dosing, split dosing, dose fractionation, etc.) and premedications. Translational modeling approaches such as mechanistic quantitative systems pharmacology models were also developed to optimize the dose in the clinic to minimize the CRS. In addition, CRS could also result in drug-drug interaction (DDI) risks due to the suppression of CYP enzymes and transporters by the proinflammatory cytokines. Physiologically-based pharmacokinetic approaches have been utilized to assess CRS mediated DDI risks. This activity will focus on the current scientific aspects for CRS and its implications in drug development as well as future perspectives. Learners who complete this activity will have enhanced knowledge utilizing case examples and discussions.
Target Audience:
Interprofessional team of graduate students, postdoctoral fellows/trainees and professionals in the field of pharmacy, pharmacometrics, clinical pharmacology and clinical pharmacy practice. This activity is applicable to participants across academia, pharmaceutical industry and regulatory agencies interested in expanding their knowledge in cytokine release syndrome.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe the cytokine release syndrome (CRS);
- Discuss the implication of CRS in drug development;
- Explain the utility of modeling approaches for prediction of CRS;
- Describe the utility of modeling approaches for estimating CRS mediated DDI.
Benjamin Colton (Moderator)
Section Chief, Clinical Pharmacy Specialists
National Institutes of Health
Dr. Colton received his Doctor of Pharmacy from Drake University before completing a postdoctoral fellowship in Infectious Diseases Pharmacotherapy at the University of Illinois at Chicago. In 2015, Dr. Colton joined the NIH Clinical Center's Pharmacy Department. As the Infectious Diseases and Immunology Clinical Pharmacy Specialist, Dr. Colton collaborates with NIAID Intramural Research Program Clinical Investigators on the design, implementation, conduct, and interpretation of early phase clinical trials. His contributions to this translational research include proctocol study design, dose selection, dose modification, risk management strategies, and pharmacometric approaches and analysis. Current collaborations include research evaluating immunomodulating therapies for patients with primary immunodeficiencies and autoinflammatory disorders and optimizing antimicrobial therapy for fungal and mycobacterial disease. Further, Dr. Colton maintains a clinical practice at the NIH Clinical Center, leveraging his expertise to support the pharmacotherapy needs of these unique patient populations. Collectively, these collaborations and patient care advance the knowledge and understanding of the complexity of the immune system, the interface between host immunity and pathogen, and pioneering interventions to modulate these complex interactions to improve the health of patients with primary immunodeficiencies, autoinflammatory conditions, disseminated fungal and mycobacterial infections, and their accompanying complications.
Yanke Yu
Distinguished Scientist
Genentech Inc/Roche
Dr. Yanke Yu, is a distinguished scientist of clinical pharmacology in Genentech Inc. Prior to Genentech, Dr. Yu held positions in Pfizer Inc. and Eisai Inc. Dr. Yu has a wealth of experience in clinical pharmacology, and modeling and simulation. Following a 13+ year industry career, Dr. Yu contributed to multiple products regulatory approvals in both oncology and immunology. Prior to his industry career, Dr. Yu completed his Ph.D. in Pharmaceutical Sciences at the University of Michigan. Dr. Yu is a prolific publisher, with 39 peer-reviewed articles and 50+ abstracts/posters/oral presentations.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information